Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2023.09.097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global, regional, and national burden of esophageal cancer: a systematic analysis of the Global Burden of Disease Study 2021.
Biomark Res
January 2025
Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Background And Objective: Esophageal cancer (EC) is the seventh most prevalent cancer globally and the sixth leading cause of cancer-related mortality. This study aimed to provide an updated stratified assessment of rates in EC incidence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021 by sex, age, and Socio-demographic Index (SDI) at global, regional, and national levels, as well as to project the future trends of EC both globally and regionally.
Methods: Data about age-standardized rates (ASRs) of incidence (ASIR), mortality (ASDR), probability of death (ASPoD) and DALYs (ASDALYRs) of EC were obtained from the 2021 Global Burden of Disease (GBD) study.
Does a multimedia education program work as a remedy for stress and burden in family caregivers of elderly heart attack patients? A clinical trial study.
BMC Nurs
January 2025
Department of Nursing, Bandar Gaz Branch, Islamic Azad University, Bandar Gaz, Iran.
Background: Supportive care has been found to improve quality of life and reduce the disease burden for aging individuals. After a heart attack, elderly patients often require a caregiver. In developing communities, caregiving responsibilities frequently fall on family members.
View Article and Find Full Text PDFClinically meaningful classes of financial toxicity for patients with diabetes.
J Patient Rep Outcomes
January 2025
Department of Physical Medicine and Rehabilitation, University of Michigan, 1540 E. Hospital Dr, Ann Arbor, MI, 48109, USA.
Aims: This study aims to improve the interpretability and clinical utility of the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) by identifying distinct financial toxicity classes in adults with diabetes.
Methods: Data included a sample of 600 adults with Type 1 or Type 2 diabetes and high A1c. Latent Class Analysis was used to identify subgroups of patients based on COST-FACIT score patterns.
Highlights of the 2024 Chinese hypertension guidelines.
Hypertens Res
January 2025
Department of Hypertension, Peking University People's Hospital, Beijing, China.
The 2024 Chinese hypertension guidelines has been recently issued by Chinese Hypertension League (CHL), joint with partner societies. Since the 2018 guidelines was released, amount of evidence accumulated, in favor of intensive blood pressure (BP) control. New drugs and devices, innovative concepts and new insights have been introduced into hypertension management.
View Article and Find Full Text PDFHome high-flow therapy during recovery from severe chronic obstructive pulmonary disease (COPD) exacerbation: a mixed-methods feasibility randomised control trial.
BMJ Open Respir Res
January 2025
Lane Fox Clinical Respiratory Physiology Research Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Introduction: Patients recovering from severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have a 30-day readmission rate of 20%. This study evaluated the feasibility of conducting a randomised controlled trial to evaluate clinical, patient-reported and physiological effects of home high-flow therapy (HFT) in addition to usual medical therapy, in eucapnic patients recovering from AECOPD to support the design of a phase 3 trial.
Methods: A mixed-methods feasibility randomised controlled trial (quantitative primacy, concurrently embedded qualitative evaluation) (ISRCTN15949009) recruiting consecutive non-obese patients hospitalised with AECOPD not requiring acute non-invasive ventilation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!